Latest / Let's Talk Risk! Podcast / Deep Dive: When Patient Preference Becomes Regulatory Evidence

Transcript

Deep Dive: When Patient Preference Becomes Regulatory Evidence · Let's Talk Risk! Podcast

• 0:00
  SPEAKER_00: Imagine sitting across from the FDA and you're sliding
• 0:03
  SPEAKER_00: a pivotal clinical trial report across the table.
• 0:06
  SPEAKER_01: Oh, boy.
• 0:06
  SPEAKER_00: Yeah.
• 0:07
  SPEAKER_00: And the raw data on your novel implantable device shows an 80% serious adverse event rate.
• 0:14
  SPEAKER_00: 80%.
• 0:15
  SPEAKER_01: Which is just, I mean, that's catastrophic on paper.
• 0:17
  SPEAKER_00: Right.
• 0:17
  SPEAKER_00: And your acute kidney injury rate is sitting at 40%.
• 0:21
  SPEAKER_00: Under the traditional regulatory paradigm,
• 0:23
  SPEAKER_00: a quality and regulatory affairs VP looking at those numbers is doing two things.
• 0:29
  SPEAKER_00: Uh...
• 0:29
  SPEAKER_00: Drafting the project as postmortem and quietly updating their resume?
• 0:33
  SPEAKER_01: Exactly.
• 0:34
  SPEAKER_01: You're packing your desk.
• 0:35
  SPEAKER_00: Because the assumption has always been that safety thresholds are rigid,
• 0:38
  SPEAKER_00: you know, objective lines in the sand.
• 0:40
  SPEAKER_00: But in a landmark case,
• 0:41
  SPEAKER_00: one sponsor took that exact data,
• 0:44
  SPEAKER_00: that brutal 80% SAE rate, and used it to secure a PMA approval.
• 0:48
  SPEAKER_00: It's wild.
• 0:49
  SPEAKER_00: Today, we are unpacking the mechanism that made that possible.
• 0:52
  SPEAKER_00: Our mission in this deep dive is to equip you,
• 0:55
  SPEAKER_00: the QRA executive,
• 0:56
  SPEAKER_00: with a highly strategic,
• 0:58
  SPEAKER_00: technical,
• 0:58
  SPEAKER_00: and ROI-focused blueprint of the FDA is March 30,
• 1:01
  SPEAKER_00: 2026, And
• 1:06
  SPEAKER_01: the paradigm shift here is just profound.
• 1:08
  SPEAKER_01: When we look at this 33-page final guidance document,
• 1:12
  SPEAKER_01: along with the detailed regulatory breakdowns we've sourced from RAPS,
• 1:16
  SPEAKER_01: Pure Global,
• 1:17
  SPEAKER_01: and an audio case study of that exact PMA rescue we just mentioned,
• 1:21
  SPEAKER_01: A completely new regulatory architecture emerges.
• 1:24
  SPEAKER_00: Yeah.
• 1:25
  SPEAKER_01: I mean, the historical mindset dictated that the FDA alone decided what constituted
• 1:29
  SPEAKER_01: a mathematically acceptable safety profile.
• 1:31
  SPEAKER_00: Right.
• 1:32
  SPEAKER_00: They held all the carbs.
• 1:33
  SPEAKER_01: Exactly.
• 1:33
  SPEAKER_01: But the 2026 guidance fundamentally rewrites the benefit risk equation across
• 1:38
  SPEAKER_01: the total product lifecycle, the TPLC.
• 1:41
  SPEAKER_01: The FDA now formally accepts rigorous mathematical proof of
• 1:45
  SPEAKER_01: a patient's personal risk tolerance as valid scientific evidence.
• 1:49
  SPEAKER_00: So the subjective desperation of a patient population has been converted into
• 1:53
  SPEAKER_00: a quantifiable, heavily regulated statistical model.
• 1:56
  SPEAKER_01: That's exactly it.
• 1:57
  SPEAKER_01: It's taking human emotion and putting it on a utility curve.
• 2:00
  SPEAKER_00: And that conversion is what generates the executive ROI.
• 2:04
  SPEAKER_00: Because before we get into the heavy compliance mandates of how
• 2:08
  SPEAKER_00: to actually design these studies,
• 2:10
  SPEAKER_00: you know,
• 2:10
  SPEAKER_00: the strict rules in Section V of the guidance,
• 2:12
  SPEAKER_00: we have to establish why a QRAVP should be allocating budget to this in
• 2:17
  SPEAKER_00: the first place.
• 2:18
  SPEAKER_01: Yeah, because these studies aren't cheap.
• 2:19
  SPEAKER_00: No, they're not.
• 2:20
  SPEAKER_00: We're talking about rescuing borderline clinical trials,
• 2:24
  SPEAKER_00: securing subpopulation approvals,
• 2:26
  SPEAKER_00: radically downsizing clinical trial enrollment targets,
• 2:29
  SPEAKER_00: and in some cases bypassing clinical trials entirely for indication expansions.
• 2:34
  SPEAKER_00: Right.
• 2:35
  SPEAKER_00: But to unlock any of that, we have to isolate a fundamental industry trap first.
• 2:41
  SPEAKER_00: There is a persistent,
• 2:42
  SPEAKER_00: expensive misconception that patient-reported outcomes,
• 2:46
  SPEAKER_00: PROs, and patient preference information, PPI, are interchangeable.
• 2:50
  SPEAKER_00: Oh, yeah.
• 2:50
  SPEAKER_01: And conflating those two will guarantee your rejected submission seen all the time.
• 2:54
  SPEAKER_01: A PRO is a snapshot of clinical efficacy.
• 2:57
  SPEAKER_01: Right.
• 2:57
  SPEAKER_01: You ask a patient to rate their joint pain on a scale of 1 to 10 after receiving
• 3:00
  SPEAKER_01: an orthopedic implant, or,
• 3:02
  SPEAKER_01: you know,
• 3:02
  SPEAKER_01: you have them fill out a standardized quality of life questionnaire at
• 3:05
  SPEAKER_01: a six-month follow-up.
• 3:06
  SPEAKER_01: It simply measures how the patient feels as a direct result of the therapy.
• 3:11
  SPEAKER_01: It is data generated by the device's performance.
• 3:14
  SPEAKER_01: PPI is entirely different.
• 3:16
  SPEAKER_01: Patient preference information measures the complex,
• 3:19
  SPEAKER_01: hypothetical tradeoffs a patient is willing to make before they ever receive
• 3:22
  SPEAKER_01: the therapy.
• 3:23
  SPEAKER_00: It captures the value they assign to specific clinical outcomes versus specific clinical risks.
• 3:29
  SPEAKER_01: Exactly.
• 3:29
  SPEAKER_01: The question shifts from does this device reduce your daily pain to would you accept
• 3:35
  SPEAKER_01: a 20% absolute risk of a systemic infection up front and a 10% risk of
• 3:40
  SPEAKER_01: a surgical revision in exchange for a 50% probability
• 3:44
  SPEAKER_01: of eliminating your daily pain?
• 3:45
  SPEAKER_00: Wow.
• 3:46
  SPEAKER_00: Okay.
• 3:46
  SPEAKER_01: Yeah.
• 3:47
  SPEAKER_01: So PPI maps the breaking point of the patient's risk tolerance.
• 3:50
  SPEAKER_01: It establishes preference heterogeneity,
• 3:53
  SPEAKER_01: acknowledging that the theoretical average patient doesn't exist.
• 3:56
  SPEAKER_01: Some patients are highly risk averse.
• 3:58
  SPEAKER_01: Others are willing to accept massive safety risks to achieve a specific benefit.
• 4:02
  SPEAKER_00: Which brings us back to the hook,
• 4:03
  SPEAKER_00: the alpha pump case study,
• 4:04
  SPEAKER_00: because this is the perfect distillation
• 4:06
  SPEAKER_00: of preference sensitive decision making rescuing a seemingly doomed PMA.
• 4:11
  SPEAKER_01: Absolutely.
• 4:12
  SPEAKER_00: So the alpha pump is a wirelessly charged implant designed for adult patients
• 4:16
  SPEAKER_00: with liver cirrhosis who suffer from refractory acytes,
• 4:19
  SPEAKER_00: which is a condition where massive,
• 4:21
  SPEAKER_00: debilitating amounts of fluid accumulate in the abdomen.
• 4:24
  SPEAKER_01: And the baseline standard of care for these patients is incredibly severe.
• 4:28
  SPEAKER_01: It involves large volume paracentesis, or LVP.
• 4:31
  SPEAKER_00: Which is awful!
• 4:33
  SPEAKER_01: It's brutal.
• 4:34
  SPEAKER_01: Patients must travel to a clinic every week or two,
• 4:36
  SPEAKER_01: have a large bore needle inserted into their abdomen,
• 4:39
  SPEAKER_01: and remain there while several liters of fluid are physically drained.
• 4:43
  SPEAKER_00: Right.
• 4:43
  SPEAKER_01: It utterly dominates their existence.
• 4:45
  SPEAKER_01: Gripping-way mobility, autonomy, quality of life.
• 4:49
  SPEAKER_01: So Sequana Medical ran the Poseidon Pivotal trial to test the alpha pump against this baseline.
• 4:55
  SPEAKER_00: And the data from Poseidon yielded that 80% serious adverse event rate
• 4:59
  SPEAKER_00: through 24 months alongside the 40% acute kidney injury rate.
• 5:03
  SPEAKER_00: Pump pocket infections, catheter blockages requiring surgical intervention.
• 5:07
  SPEAKER_01: Yeah, tough numbers.
• 5:09
  SPEAKER_00: It's really tough.
• 5:10
  SPEAKER_00: If you look at this purely from a traditional objective safety threshold,
• 5:15
  SPEAKER_00: the device appears unapprovable.
• 5:17
  SPEAKER_00: My immediate thought as a regulatory strategist looking at that is liability
• 5:21
  SPEAKER_00: and statutory obligation.
• 5:23
  SPEAKER_00: The FDA's mandate is to ensure safety and efficacy.
• 5:27
  SPEAKER_00: How does factoring in a patient's subjective hatred of their standard
• 5:30
  SPEAKER_00: of care circumvent the statutory requirement that a device must be safe?
• 5:34
  SPEAKER_00: I mean, risk is risk.
• 5:36
  SPEAKER_00: An 80% SAE is an 80% SAE.
• 5:39
  SPEAKER_01: Well, see,
• 5:39
  SPEAKER_01: the 2026 guidance clarifies that safety is no longer a monolithic,
• 5:43
  SPEAKER_01: uniform threshold applied indiscriminately across all therapeutic areas.
• 5:48
  SPEAKER_01: Safety is now relative to the mathematically validated preference of the end user.
• 5:52
  SPEAKER_00: Okay, so how did they prove that mathematically?
• 5:54
  SPEAKER_01: To capture this,
• 5:54
  SPEAKER_01: the sponsor partnered with RTI Health Solutions to conduct
• 5:57
  SPEAKER_01: a discrete choice experiment, a DCE.
• 6:00
  SPEAKER_01: And the FDA views a properly structured DCE as valid scientific evidence.
• 6:05
  SPEAKER_01: In a DCE, you do not just ask a patient, hey, would you like this pump?
• 6:08
  SPEAKER_01: You force them into a structured, exhaustive series of tradeoffs.
• 6:12
  SPEAKER_01: You present Profile A,
• 6:14
  SPEAKER_01: which entirely eliminates the need for paracentesis,
• 6:17
  SPEAKER_01: but carries a high risk of kidney injury and surgical revision.
• 6:20
  SPEAKER_00: Okay.
• 6:21
  SPEAKER_01: The methodology here is critical because they are generating a utility curve.
• 6:24
  SPEAKER_01: Exactly.
• 6:24
  SPEAKER_01: The respondent is taken through perhaps 15 or 20 of these choice tasks.
• 6:38
  SPEAKER_01: Right.
• 6:38
  SPEAKER_01: Right.
• 6:39
  SPEAKER_01: Right.
• 6:53
  SPEAKER_01: Statisticians can calculate the exact beta coefficients.
• 6:56
  SPEAKER_01: That's the relative weight the patient population signs to each attribute.
• 6:59
  SPEAKER_01: They pinpoint the exact moment the patient says, okay, the risk is now too high.
• 7:03
  SPEAKER_01: I will just stick with the needle.
• 7:04
  SPEAKER_00: This operates a lot like corporate financial hedging or actuarial risk modeling.
• 7:07
  SPEAKER_01: Yes.
• 7:08
  SPEAKER_00: You are identifying a known quantifiable high yield risk,
• 7:12
  SPEAKER_00: in this case,
• 7:12
  SPEAKER_00: the revision surgery,
• 7:14
  SPEAKER_00: and accepting it to eliminate a systemic debilitating baseline cost,
• 7:18
  SPEAKER_00: which is the paracentesis.
• 7:21
  SPEAKER_00: The utility curve mathematically proved that patients were willing to accept
• 7:24
  SPEAKER_00: a greater than 35% risk of a minor procedure,
• 7:27
  SPEAKER_00: like a device explained or revision, to escape their standard of care.
• 7:31
  SPEAKER_01: When you overlay that mathematically validated threshold onto the clinical data from
• 7:35
  SPEAKER_01: the Poseidon trial, the narrative completely flips.
• 7:39
  SPEAKER_01: The actual trial rate for minor revisions was 20%.
• 7:42
  SPEAKER_01: So while 20% looks catastrophic on a traditional risk matrix,
• 7:46
  SPEAKER_01: it is 15 percentage points below the patient's maximum acceptable risk, the MAR.
• 7:51
  SPEAKER_00: That's fascinating.
• 7:52
  SPEAKER_01: Right.
• 7:52
  SPEAKER_01: The FDA evaluated the clinical data through the lens of the utility curve.
• 7:56
  SPEAKER_01: The subjective desperation of the cirrhosis patient was converted into
• 7:59
  SPEAKER_01: a quantified minimal acceptable benefit, a MA.
• 8:03
  SPEAKER_01: Because the device's performance fell safely within
• 8:05
  SPEAKER_01: the validated preference threshold of that specific subpopulation,
• 8:09
  SPEAKER_01: the PMA was approved.
• 8:10
  SPEAKER_00: That concept,
• 8:11
  SPEAKER_00: the minimal acceptable benefit,
• 8:13
  SPEAKER_00: is a massive lever for QRA leaders because it allows you
• 8:16
  SPEAKER_00: to define highly specific performance goals.
• 8:19
  SPEAKER_00: If you can define the MA mathematically,
• 8:21
  SPEAKER_00: you can potentially downsize costly clinical trial enrollment targets.
• 8:25
  SPEAKER_01: Huge cost savings there.
• 8:26
  SPEAKER_00: Absolutely.
• 8:27
  SPEAKER_00: You aren't powering a trial to prove an arbitrary safety margin.
• 8:30
  SPEAKER_00: You are powering it to clear the specific patient-validated MA.
• 8:35
  SPEAKER_00: Oh, this is one of my favorite examples.
• 8:36
  SPEAKER_00: Yeah.
• 8:36
  SPEAKER_00: Okay.
• 8:36
  SPEAKER_00: Okay.
• 8:37
  SPEAKER_00: Okay.
• 9:03
  SPEAKER_01: The sponsor wanted to expand the indication to allow for solo home use,
• 9:07
  SPEAKER_01: granting the patient complete autonomy.
• 9:09
  SPEAKER_00: The roadblock there is immediate and obvious.
• 9:11
  SPEAKER_00: You cannot run a clinical trial for that indication.
• 9:14
  SPEAKER_00: No.
• 9:14
  SPEAKER_00: No institutional review board on the planet is going to approve a trial protocol
• 9:19
  SPEAKER_00: where you intentionally leave a hemodialysis patient alone in a room to see how many
• 9:24
  SPEAKER_00: of them experience a fatal needle dislodgement and bleed out.
• 9:27
  SPEAKER_01: Yeah, that's not happening.
• 9:28
  SPEAKER_00: The clinical pathway was completely blocked.
• 9:31
  SPEAKER_01: So with a clinical trial off the table, the sponsor pivoted to a PPI strategy.
• 9:36
  SPEAKER_01: However,
• 9:37
  SPEAKER_01: instead of a discrete choice experiment like we saw with the alpha pump,
• 9:41
  SPEAKER_01: they utilized the threshold technique, or TT.
• 9:44
  SPEAKER_00: Right.
• 9:45
  SPEAKER_01: The threshold technique is the optimal statistical model when you have
• 9:48
  SPEAKER_01: a single fixed clinical benefit,
• 9:51
  SPEAKER_01: in this case,
• 9:52
  SPEAKER_01: the total autonomy of solo therapy,
• 9:55
  SPEAKER_01: and you need to find the maximum acceptable limit for a specific severe risk.
• 9:59
  SPEAKER_00: So they tested the risk of death and the risk of needle dislodgement.
• 10:02
  SPEAKER_01: Yes.
• 10:02
  SPEAKER_00: They surveyed 142 patients.
• 10:04
  SPEAKER_00: And the threshold technique...
• 10:06
  SPEAKER_00: Forces the patient to weigh that single fixed benefit
• 10:09
  SPEAKER_00: against incrementally increasing probabilities of the catastrophic risk.
• 10:12
  SPEAKER_00: The data proved that the patient population heavily valued their autonomy.
• 10:17
  SPEAKER_00: They were statistically willing to accept the higher,
• 10:19
  SPEAKER_00: potentially fatal risks of solo therapy in exchange for not having to rely on
• 10:24
  SPEAKER_00: a caregiver.
• 10:25
  SPEAKER_01: And the result was that the FDA reviewed the threshold technique data,
• 10:29
  SPEAKER_01: accepted the mathematically validated preference threshold,
• 10:32
  SPEAKER_01: and granted the 510k indication expansion.
• 10:36
  SPEAKER_01: The sponsor secured a major market advantage without ever enrolling a single patient
• 10:40
  SPEAKER_01: in a new, impossible clinical trial.
• 10:43
  SPEAKER_01: Millions of dollars and years of development time were saved
• 10:46
  SPEAKER_01: because they successfully converted subjective patient preference
• 10:49
  SPEAKER_01: into objective regulatory data.
• 10:51
  SPEAKER_00: But the underlying reality here is that capturing that ROI is incredibly difficult.
• 10:56
  SPEAKER_01: Oh, really?
• 10:56
  SPEAKER_00: It requires navigating a highly prescriptive minefield of regulatory design rules.
• 11:01
  SPEAKER_00: Because the FDA didn't just open the floodgates and say, hey, send us your surveys.
• 11:04
  SPEAKER_01: No, no, no.
• 11:05
  SPEAKER_00: Section V of the final guidance outlines strict compliance mandates.
• 11:10
  SPEAKER_00: If a QRA team does not execute these methodologies perfectly,
• 11:13
  SPEAKER_00: the FDA will outright reject the multi-million dollar prefix study.
• 11:18
  SPEAKER_00: The most immediate compliance trap involves how the survey is administered to the patient.
• 11:22
  SPEAKER_01: Historically,
• 11:23
  SPEAKER_01: a sponsor might contract a third-party vendor to email a survey link to
• 11:27
  SPEAKER_01: a patient panel.
• 11:29
  SPEAKER_01: The patient clicks through it on their phone while watching television,
• 11:32
  SPEAKER_01: and the sponsor submits the resulting data.
• 11:35
  SPEAKER_01: The 2026 guidance explicitly bans this casual approach.
• 11:39
  SPEAKER_01: If a preference survey is self-administered,
• 11:42
  SPEAKER_01: meaning the patient is completing it independently,
• 11:44
  SPEAKER_01: without real-time guidance and moderation
• 11:46
  SPEAKER_01: from trained clinical research— Staff participants are now required to complete
• 11:50
  SPEAKER_01: a mandatory educational tutorial followed by a formal comprehension quiz
• 11:55
  SPEAKER_01: before they're even allowed to view the preference questions.
• 11:58
  SPEAKER_00: And this isn't just a basic I agree checkbox at the bottom of a terms and conditions page.
• 12:02
  SPEAKER_00: The sponsor has to document the results of those comprehension quizzes
• 12:05
  SPEAKER_00: and submit them as supportive evidence in the regulatory filing.
• 12:09
  SPEAKER_00: If you cannot objectively prove that the respondent thoroughly understood
• 12:13
  SPEAKER_00: the clinical tradeoffs being presented,
• 12:15
  SPEAKER_00: The FDA considers the entire dataset invalid.
• 12:19
  SPEAKER_01: The statistical reasoning behind this mandate is sound.
• 12:22
  SPEAKER_01: If a patient does not genuinely comprehend the difference between
• 12:25
  SPEAKER_01: a transient acute kidney injury and a chronic systemic infection,
• 12:29
  SPEAKER_01: the utility curve generated by their choices is mathematically worthless.
• 12:33
  SPEAKER_01: It is noise.
• 12:34
  SPEAKER_01: The FDA requires you to prove you have isolated the true preference signal from
• 12:38
  SPEAKER_01: the noise of misunderstanding,
• 12:40
  SPEAKER_01: which leads to another critical boundary established in the guidance,
• 12:42
  SPEAKER_01: the commercial cost prohibition outlined in Section VG.
• 12:46
  SPEAKER_00: QRA executives need to monitor this closely when their marketing
• 12:49
  SPEAKER_00: and commercial teams get involved in survey design.
• 12:52
  SPEAKER_00: When you are establishing the attributes,
• 12:54
  SPEAKER_00: the specific variables the patient will weigh against each other,
• 12:57
  SPEAKER_00: they must be framed neutrally,
• 12:59
  SPEAKER_00: and you absolutely must exclude any commercial cost variables.
• 13:04
  SPEAKER_00: You cannot ask a patient if they would accept a device with
• 13:06
  SPEAKER_00: a slightly higher failure rate if it saved them $500 out of pocket.
• 13:10
  SPEAKER_01: Yeah, marketing teams always try to sneak that in.
• 13:12
  SPEAKER_00: They do.
• 13:13
  SPEAKER_01: But the FDA's statutory authority is limited to evaluating clinical safety
• 13:18
  SPEAKER_01: and clinical efficacy.
• 13:20
  SPEAKER_01: They do not possess the statutory mandate to regulate pricing,
• 13:23
  SPEAKER_01: insurance reimbursement tiers, or hospital purchasing contracts.
• 13:27
  SPEAKER_01: Right.
• 13:27
  SPEAKER_01: Including a financial cost attribute in
• 13:30
  SPEAKER_01: a regulatory preference survey fundamentally corrupts the clinical risk model.
• 13:34
  SPEAKER_01: It introduces a non-clinical confounding variable.
• 13:37
  SPEAKER_01: If the FDA detects that financial costs influence the patient's risk tolerance in
• 13:41
  SPEAKER_01: the data, the study is invalidated for regulatory decision making.
• 13:45
  SPEAKER_00: Because it creates an artificial risk threshold.
• 13:48
  SPEAKER_00: A patient might accept a dangerous device simply
• 13:50
  SPEAKER_00: because they are economically disadvantaged,
• 13:53
  SPEAKER_00: which the FDA obviously cannot use as a justification for clinical safety.
• 13:56
  SPEAKER_01: Exactly.
• 13:57
  SPEAKER_00: So you have to eliminate the financial variables.
• 13:59
  SPEAKER_00: But communicating the actual clinical variables accurately brings up
• 14:03
  SPEAKER_00: a massive psychological hurdle.
• 14:06
  SPEAKER_00: Yeah, health numeracy refers to a patient's capacity to process,
• 14:08
  SPEAKER_00: interpret, and act on statistical risk information.
• 14:20
  SPEAKER_01: The general population struggles immensely with probability and statistics.
• 14:24
  SPEAKER_00: Oh, for sure.
• 14:25
  SPEAKER_01: The FDA recognizes this,
• 14:26
  SPEAKER_01: and the guidance is incredibly prescriptive about the formatting and presentation
• 14:30
  SPEAKER_01: of statistical risk to prevent sponsors from manipulating patient perception.
• 14:34
  SPEAKER_00: The banned practices read like a textbook on what medical device marketing teams do every day.
• 14:39
  SPEAKER_00: You are prohibited from using fractions.
• 14:41
  SPEAKER_00: You cannot use decimals because patient might see .02 and .2 and fail
• 14:46
  SPEAKER_00: to immediately grasp the magnitude of the difference.
• 14:49
  SPEAKER_00: You absolutely cannot use changing denominators.
• 14:52
  SPEAKER_00: You cannot say one in five patients experiences localized pain,
• 14:55
  SPEAKER_00: but three in 50 experience an infection.
• 14:58
  SPEAKER_01: That specific prohibition addresses denominator neglect.
• 15:02
  SPEAKER_01: When patients see 1 in 5 versus 20 in 100,
• 15:06
  SPEAKER_01: they often perceive 1 in 5 as a more significant threat because
• 15:09
  SPEAKER_01: the numerator represents a larger proportion of the stated denominator,
• 15:13
  SPEAKER_01: even though the absolute probability is identical.
• 15:16
  SPEAKER_00: Right.
• 15:16
  SPEAKER_00: It feels bigger.
• 15:17
  SPEAKER_01: Exactly.
• 15:18
  SPEAKER_01: To eliminate this cognitive distortion,
• 15:20
  SPEAKER_01: the FDA mandates the use of absolute frequencies with a consistent denominator,
• 15:25
  SPEAKER_01: such as 20 in 1,000.
• 15:27
  SPEAKER_00: They also ban purely verbal descriptions of risk.
• 15:30
  SPEAKER_00: You cannot label an attribute as having a high risk of revision or a low risk of revision.
• 15:35
  SPEAKER_01: Because verbal descriptions are entirely subjective anchors.
• 15:39
  SPEAKER_01: A patient who has endured five invasive surgeries might consider
• 15:42
  SPEAKER_01: a 20% revision rate low risk,
• 15:45
  SPEAKER_01: while a patient newly diagnosed with a condition might consider
• 15:48
  SPEAKER_01: a 5% risk catastrophically high.
• 15:51
  SPEAKER_01: The FDA requires the subjective feeling to be anchored to an objective absolute frequency.
• 15:57
  SPEAKER_01: Furthermore,
• 15:57
  SPEAKER_01: the guidance explicitly mandates the use of validated visual aids,
• 16:02
  SPEAKER_01: specifically 100% icon grids.
• 16:05
  SPEAKER_00: It's a very specific graphical representation.
• 16:08
  SPEAKER_00: You display an array of 100 small human figures,
• 16:12
  SPEAKER_00: all shaded in one color,
• 16:13
  SPEAKER_00: with two figures shaded in a contrasting color to visually represent a 2% risk.
• 16:18
  SPEAKER_01: Yeah, it's very clear.
• 16:19
  SPEAKER_00: Yes, you have to present the whole picture.
• 16:21
  SPEAKER_00: But looking at this from an executive strategy level,
• 16:23
  SPEAKER_00: I have a fundamental question about the cognitive science here.
• 16:25
  SPEAKER_00: Okay, let's hear it.
• 16:43
  SPEAKER_00: We know human beings are not supercomputers.
• 16:45
  SPEAKER_00: Even if you meticulously design a 100% icon grid and use absolute frequencies,
• 16:51
  SPEAKER_00: a patient reviewing a complex discrete choice experiment is naturally going
• 16:55
  SPEAKER_00: to suffer from cognitive fatigue.
• 16:56
  SPEAKER_00: Oh absolutely.
• 16:57
  SPEAKER_01: They're going to mentally recode those precise statistical grids back
• 17:01
  SPEAKER_01: into heuristic buckets of low, medium, and high just to get through the survey.
• 17:07
  SPEAKER_01: It cares how the human brain simplifies complex data.
• 17:10
  SPEAKER_01: If the patient is ultimately going to use a heuristic shortcut anyway,
• 17:14
  SPEAKER_01: why is the FDA so originally obsessed with the exact graphical formatting
• 17:18
  SPEAKER_01: of these grids?
• 17:20
  SPEAKER_00: Well, the FDA is fully aware of heuristic recoding.
• 17:22
  SPEAKER_00: In fact, the statisticians at CDRH actively hunt for it in your data.
• 17:27
  SPEAKER_00: The FDA relies on formal statistical tests within the survey structure itself
• 17:32
  SPEAKER_00: to detect this exact behavior.
• 17:34
  SPEAKER_00: One common heuristic is lexicographic behavior.
• 17:36
  SPEAKER_01: Lexicographic behavior.
• 17:37
  SPEAKER_00: Yeah, where a respondent becomes overwhelmed by the complexity of the choice task
• 17:41
  SPEAKER_00: and simply focuses on a single dominant attribute,
• 17:44
  SPEAKER_00: say, the risk of infection, ignoring all other variables entirely.
• 17:47
  SPEAKER_01: Ah, I see.
• 17:48
  SPEAKER_00: If a Siri is poorly designed or lacks visual clarity,
• 17:51
  SPEAKER_00: it exacerbates this cognitive fatigue and encourages extreme heuristic recoding,
• 17:55
  SPEAKER_00: which completely flattens the nuance of the utility curve.
• 17:58
  SPEAKER_01: The visual grids are designed to enforce a minimum cognitive load.
• 18:03
  SPEAKER_01: They force the patient's brain to repeatedly confront the objective,
• 18:07
  SPEAKER_01: proportional reality of the math.
• 18:10
  SPEAKER_01: During the analysis phase, statisticians use consistency checks and holdout tasks.
• 18:15
  SPEAKER_01: So, presenting the same choice in a different format later in the survey to measure
• 18:20
  SPEAKER_01: the rate of heuristic use.
• 18:21
  SPEAKER_00: That's clever.
• 18:22
  SPEAKER_01: It is.
• 18:23
  SPEAKER_01: If the grids and tutorials were effective,
• 18:25
  SPEAKER_01: the patient's choices will demonstrate a consistent,
• 18:28
  SPEAKER_01: nuanced weighting of all attributes.
• 18:31
  SPEAKER_01: The FDA demands these specific visual formats because they mathematically reduce
• 18:36
  SPEAKER_01: the noise of cognitive fatigue,
• 18:38
  SPEAKER_01: ensuring the resulting utility curve reflects a genuine clinical threshold rather
• 18:42
  SPEAKER_01: than a stressed patient's gut reaction.
• 18:44
  SPEAKER_00: So the formatting is essentially a required That makes complete sense.
• 18:51
  SPEAKER_00: But that brings us to the operational reality.
• 18:53
  SPEAKER_00: You can spend $2 million contracting a health economics firm to build
• 18:57
  SPEAKER_00: the most robust,
• 18:58
  SPEAKER_00: visually compliant, mathematically perfect discrete choice experiment in the world.
• 19:03
  SPEAKER_00: But if you field that survey and then hand the final report to the FDA,
• 19:08
  SPEAKER_00: they will likely dismiss it entirely if they didn't agree to
• 19:11
  SPEAKER_00: the foundational parameters first.
• 19:12
  SPEAKER_01: Oh, executing a PPI study in a silo is a fatal strategic error.
• 19:18
  SPEAKER_01: The Q submission program is the operational battleground where the success
• 19:21
  SPEAKER_01: or failure of a patient preference study is determined.
• 19:24
  SPEAKER_01: A sponsor must submit their proposed methodology,
• 19:27
  SPEAKER_01: specifically their attribute tables,
• 19:29
  SPEAKER_01: to the FDA for formal alignment well before a single patient is tested.
• 19:33
  SPEAKER_00: And the attribute table is the structural skeleton of the survey.
• 19:37
  SPEAKER_00: It maps the patient-facing clinical labels to
• 19:39
  SPEAKER_00: the actual statistical ranges you expect to see in your forthcoming clinical trial.
• 19:44
  SPEAKER_00: If your engineering and clinical teams project that your novel device might carry
• 19:48
  SPEAKER_00: a 10 to 15 percent localized infection rate,
• 19:51
  SPEAKER_00: your attribute table must test patient tolerance across that spectrum
• 19:55
  SPEAKER_00: and ideally push slightly beyond it, perhaps testing up to 20 or 25 percent.
• 20:00
  SPEAKER_01: Right.
• 20:00
  SPEAKER_01: Right.
• 20:00
  SPEAKER_01: Right.
• 20:26
  SPEAKER_01: The FDA will reject the inferred data because preference curves are rarely linear.
• 20:32
  SPEAKER_01: A patient's risk tolerance might cliff drop at 16%.
• 20:36
  SPEAKER_00: Let's evaluate the risk management aspect of this.
• 20:38
  SPEAKER_00: We are sitting in a Q-sub meeting, locking in this attribute table.
• 20:42
  SPEAKER_00: We use the Q-sub to call our shot in advance, much like playing billiards.
• 20:47
  SPEAKER_00: You have to declare exactly which pocket you're aiming for.
• 20:49
  SPEAKER_00: You cannot wildly strike the Q-ball,
• 20:51
  SPEAKER_00: sink the 8-ball off three cushions by accident,
• 20:54
  SPEAKER_00: and claim it was your intended strategy.
• 20:56
  SPEAKER_00: You must declare the analytical intent.
• 20:58
  SPEAKER_01: That's a great analogy.
• 20:59
  SPEAKER_00: But what happens if the clinical reality diverges from our Q-sub projection?
• 21:04
  SPEAKER_00: Let's say our regulatory team aligns with the FDA to test a revision rate up to 20%.
• 21:09
  SPEAKER_00: We execute the survey and the utility curve clearly shows patients will accept a 20% risk.
• 21:15
  SPEAKER_00: We then run our multi-year pivotal trial and the final data shows
• 21:19
  SPEAKER_00: an actual revision rate of 22%.
• 21:20
  SPEAKER_00: Uh-oh.
• 21:21
  SPEAKER_00: That exact scenario is the nightmare keeping QRA directors awake.
• 21:37
  SPEAKER_01: That's brutal.
• 21:37
  SPEAKER_01: That's brutal.
• 22:04
  SPEAKER_01: Or in the worst case scenario, start the preference study over entirely.
• 22:07
  SPEAKER_00: Wow.
• 22:08
  SPEAKER_01: So the strategic imperative during the Q-sub is to establish
• 22:11
  SPEAKER_01: a maximum acceptable risk,
• 22:13
  SPEAKER_01: a MAR, that stretches comfortably beyond your worst case clinical projections.
• 22:18
  SPEAKER_01: Of course.
• 22:18
  SPEAKER_01: Right.
• 22:39
  SPEAKER_01: The Q-sub negotiation is a delicate balancing act between securing a wide safety net
• 22:44
  SPEAKER_01: for your clinical trial and maintaining the clinical realism of
• 22:48
  SPEAKER_01: the survey instrument.
• 22:49
  SPEAKER_00: That requires deep alignment between the clinical trial designers,
• 22:52
  SPEAKER_00: the regulatory strategists,
• 22:54
  SPEAKER_00: and the health economists before you ever speak to the agency.
• 22:56
  SPEAKER_00: Absolutely.
• 22:57
  SPEAKER_00: Another critical element of the Q-sub alignment is
• 23:00
  SPEAKER_00: the pre-specified statistical analysis plan in the SAP.
• 23:03
  SPEAKER_01: Yeah, the 2026 guidance places a heavy emphasis on the SAP to prevent data dredging,
• 23:08
  SPEAKER_01: or p-hacking.
• 23:09
  SPEAKER_01: You cannot run a preference survey,
• 23:11
  SPEAKER_01: dump the raw data into an analytical software package,
• 23:14
  SPEAKER_01: and then continuously slice and re-slice the patient demographics
• 23:17
  SPEAKER_01: until you magically discover a sub-hot.
• 23:18
  SPEAKER_01: Because if you fail to pre-specify the SAP,
• 23:21
  SPEAKER_01: the FDA will view any favorable subpopulation analysis as highly exploratory
• 23:24
  SPEAKER_00: and likely biased by the sponsor's desire to find a path to approval.
• 23:49
  SPEAKER_01: Speaking of subgroups and specific populations,
• 23:51
  SPEAKER_01: the guidance also clarifies the pathway for utilizing outside U.S.
• 23:54
  SPEAKER_01: or OUS preference data under 21 CFR A12.28.
• 23:59
  SPEAKER_00: For global medtech organizations running decentralized
• 24:02
  SPEAKER_00: or international clinical trials, this is a massive operational factor.
• 24:07
  SPEAKER_00: The FDA has stated they will accept OUS preference data, but the regulatory burn of proof...
• 24:13
  SPEAKER_00: Shifts heavily onto the sponsor.
• 24:15
  SPEAKER_00: You have to definitively prove cultural and health system applicability.
• 24:19
  SPEAKER_01: Yes.
• 24:19
  SPEAKER_01: The underlying mechanism here is that risk tolerance is intimately tied
• 24:24
  SPEAKER_01: to socioeconomic context.
• 24:26
  SPEAKER_00: Right.
• 24:26
  SPEAKER_01: A patient residing in a European country with
• 24:29
  SPEAKER_01: a robust nationalized social safety net,
• 24:32
  SPEAKER_01: comprehensive disability coverage,
• 24:34
  SPEAKER_01: and zero out-of-pocket health care costs might evaluate the risk of
• 24:38
  SPEAKER_01: a severe adverse event entirely differently than a patient in the United States.
• 24:42
  SPEAKER_00: That makes total sense.
• 24:43
  SPEAKER_01: Furthermore, the baseline standard of care might vary significantly between regions.
• 24:47
  SPEAKER_01: If a QRA leader submits a discrete-choice experiment connected entirely
• 24:51
  SPEAKER_01: with patients in Germany,
• 24:52
  SPEAKER_01: they must provide a formal,
• 24:54
  SPEAKER_01: evidence-based justification detailing why the German standard of care
• 24:57
  SPEAKER_01: and risk tolerance profile directly translates to the specific patient population
• 25:01
  SPEAKER_01: in Ohio or Texas.
• 25:02
  SPEAKER_00: And if they don't buy it.
• 25:03
  SPEAKER_01: If the FDA deterrents the socioeconomic variables confound the risk profile,
• 25:08
  SPEAKER_01: they will disregard the OUS data.
• 25:11
  SPEAKER_00: The strategy clearly requires rigorous upfront planning.
• 25:14
  SPEAKER_00: But the value of a meticulously executed PPI study extends far beyond the moment
• 25:19
  SPEAKER_00: the FDA hands over the PMA or 510k clearance.
• 25:23
  SPEAKER_00: The guidance details how this data impacts the device across the entire total product lifecycle.
• 25:29
  SPEAKER_00: Moving into the post-market phase,
• 25:30
  SPEAKER_00: one of the most aggressive and highly strategic applications of PPI is deploying it
• 25:35
  SPEAKER_00: as a post-market compliance and enforcement shield.
• 25:38
  SPEAKER_01: This represents a fascinating evolution in FDA enforcement discretion.
• 25:42
  SPEAKER_01: The guidance explicitly reveals how robust patient preference information influences
• 25:46
  SPEAKER_01: the agency's decisions regarding administrative actions,
• 25:49
  SPEAKER_01: enforcement protocols, and compliance crackdowns.
• 25:51
  SPEAKER_00: Okay, lay this out for us.
• 25:52
  SPEAKER_01: Consider a scenario where a device has been on the market for three years and
• 25:55
  SPEAKER_01: a post-market surveillance signal identifies that
• 25:58
  SPEAKER_01: the device is technically not conforming to a specific performance standard.
• 26:02
  SPEAKER_00: Historically,
• 26:03
  SPEAKER_00: a technical nonconformance almost automatically triggers a recall,
• 26:07
  SPEAKER_00: a cessation of distribution, or a warning letter.
• 26:10
  SPEAKER_00: The regulatory reflex is to pull the product.
• 26:13
  SPEAKER_01: Wow.
• 26:34
  SPEAKER_01: It provides the FDA with the mathematical cover they need to keep a non-conforming
• 26:38
  SPEAKER_01: but critical device in the hands of physicians.
• 26:40
  SPEAKER_01: But there is a massive operational tradeoff.
• 26:58
  SPEAKER_00: If you win pre-market approval or
• 27:00
  SPEAKER_00: if you secure post-market enforcement discretion based heavily on preference data,
• 27:04
  SPEAKER_00: the FDA will almost certainly mandate strict conditions
• 27:07
  SPEAKER_00: of approval regarding product labeling.
• 27:09
  SPEAKER_01: Yeah, the data cannot live exclusively in a regulatory filing cabinet.
• 27:13
  SPEAKER_01: The FDA requires the sponsor to translate the complex beta coefficients
• 27:18
  SPEAKER_01: and utility curves of the discrete choice model into plain language,
• 27:22
  SPEAKER_01: patient-facing documents known as shared decision-making tools.
• 27:27
  SPEAKER_00: These tools function as informed consent forms on a completely different operational level.
• 27:32
  SPEAKER_01: Oh, they are highly structured clinical documents.
• 27:35
  SPEAKER_01: The guidance stipulates that physicians must physically walk through these tools
• 27:39
  SPEAKER_01: with the individual patient in the examination room before the device is prescribed
• 27:43
  SPEAKER_01: or implanted.
• 27:43
  SPEAKER_01: Right.
• 27:44
  SPEAKER_01: The objective is to verify that the specific patient sitting on
• 27:47
  SPEAKER_01: the exam table genuinely shares the exact risk tolerance profile of
• 27:51
  SPEAKER_01: the mathematical model that justified the device's approval in the first place.
• 27:55
  SPEAKER_01: That ensures the macro-level statistical model accurately maps
• 27:57
  SPEAKER_01: the micro-level clinical reality of the individual.
• 27:59
  SPEAKER_01: But I want to scrutinize the boundaries of this enforcement shield concept
• 28:02
  SPEAKER_01: because there is a very dangerous extrapolation a QRA team could make here.
• 28:06
  SPEAKER_00: Okay.
• 28:22
  SPEAKER_00: If a company gets hit with a devastating 483 observation or a warning letter for
• 28:27
  SPEAKER_00: a blatant systemic manufacturing defect,
• 28:30
  SPEAKER_00: let's say they have a massive sterile barrier failure on the packaging line,
• 28:34
  SPEAKER_00: or their software engineering is completely undocumented and riddled
• 28:37
  SPEAKER_00: with catastrophic bugs,
• 28:39
  SPEAKER_00: they cannot simply slide a utility curve across the table and argue, yes,
• 28:43
  SPEAKER_00: our quality system is a disaster,
• 28:45
  SPEAKER_00: but the patients are desperate, so you must let us keep selling it.
• 28:49
  SPEAKER_00: There has to be a hard statutory limit to preference data.
• 28:52
  SPEAKER_01: Oh, absolutely.
• 28:53
  SPEAKER_01: There is an absolute limit.
• 28:54
  SPEAKER_01: And the FDA aggressively defines it in Section IXE of the guidance,
• 28:58
  SPEAKER_01: which covers the hard safety limits.
• 28:59
  SPEAKER_00: Okay, good.
• 29:00
  SPEAKER_01: PPI is a highly sophisticated regulatory lever.
• 29:03
  SPEAKER_01: It evaluates and quantifies clinical risk tolerance.
• 29:06
  SPEAKER_01: Makes sense.
• 29:34
  SPEAKER_01: The FDA draws a very sharp,
• 29:35
  SPEAKER_01: impenetrable boundary between a patient mathematically accepting
• 29:39
  SPEAKER_01: the inherent unavoidable clinical risks of a novel,
• 29:41
  SPEAKER_01: life-saving therapy versus a manufacturer failing
• 29:44
  SPEAKER_01: to execute basic quality assurance.
• 29:46
  SPEAKER_01: If your sterile barrier is failing,
• 29:48
  SPEAKER_01: no amount of patient preference data will prevent a mandatory recall.
• 29:51
  SPEAKER_00: That distinction protects the structural integrity of the entire regulatory framework.
• 29:56
  SPEAKER_00: It allows for flexibility and clinical risk without compromising
• 29:59
  SPEAKER_00: the baseline standards of manufacturing quality.
• 30:03
  SPEAKER_00: So as we synthesize this blueprint for the quality
• 30:06
  SPEAKER_00: and regulatory VPs listening today, the core takeaway is absolute.
• 30:10
  SPEAKER_00: Patient preference is no longer a soft qualitative afterthought.
• 30:14
  SPEAKER_01: No, it's not.
• 30:15
  SPEAKER_00: It is not anecdotal evidence relegated to marketing brochures or focus groups.
• 30:20
  SPEAKER_01: It has been elevated to quantitative,
• 30:22
  SPEAKER_01: valid scientific evidence governed by strict statistical rules.
• 30:26
  SPEAKER_00: When executed correctly,
• 30:28
  SPEAKER_00: adhering strictly to the Section V design rules and leveraging the QSub process
• 30:32
  SPEAKER_00: to lock in the SAP and attribute tables,
• 30:34
  SPEAKER_00: PPI can rescue borderline pivotal trials like the AlphaPunk.
• 30:38
  SPEAKER_01: Which leaves us with a final highly strategic concept to consider,
• 30:41
  SPEAKER_01: drawn directly from the pure global regulatory analysis.
• 30:45
  SPEAKER_01: Pure Global noted a critical alignment.
• 30:48
  SPEAKER_01: This 2026 FDA guidance aligns conceptually with the foundational principles of
• 30:52
  SPEAKER_01: the European Union medical device regulation and in vitro diagnostic regulation,
• 30:57
  SPEAKER_01: specifically regarding post-market clinical follow-up, or PMCF.
• 31:01
  SPEAKER_00: The international implications there are massive.
• 31:03
  SPEAKER_01: Consider the long-term global strategy.
• 31:06
  SPEAKER_01: If a U.S.-based regulatory team successfully utilizes
• 31:09
  SPEAKER_01: a complex discrete-choice experiment to mathematically justify a 20% revision rate
• 31:13
  SPEAKER_01: to the FDA and secures a PMA based on that utility curve,
• 31:17
  SPEAKER_01: how will the notified bodies in Europe react to that exact same math?
• 31:21
  SPEAKER_00: That's the million-dollar question.
• 31:22
  SPEAKER_01: Could this FDA guidance effectively become a global regulatory Trojan horse,
• 31:26
  SPEAKER_01: standardizing the mathematical proof of risk tolerance across international borders?
• 31:42
  SPEAKER_00: That is a strategic avenue every VP should be actively mapping out
• 31:45
  SPEAKER_00: with their global regulatory teams.
• 31:47
  SPEAKER_00: It highlights the profound evolution of this field.
• 31:49
  SPEAKER_00: We began this deep dive discussing rigid safety thresholds and objective lines in the sand.
• 31:54
  SPEAKER_00: But as the 2026 guidance proves,
• 31:57
  SPEAKER_00: when you apply rigorous statistical modeling to the messy,
• 32:00
  SPEAKER_00: subjective reality of human suffering and preference,
• 32:03
  SPEAKER_00: the regulatory landscape doesn't become murkier.
• 32:05
  SPEAKER_00: It actually becomes more precise.
• 32:06
  SPEAKER_00: It just demands an entirely new level of executive navigation.